Claudio Belluco

Summary

Affiliation: Centro di Riferimento Oncologico
Country: Italy

Publications

  1. ncbi Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discovery
    Riccardo Alessandro
    Department of Biopathology and Biomedical Methodology, Universita di Palermo, Palermo, Italy
    Clin Colorectal Cancer 4:396-402. 2005
  2. ncbi Gene expression profile of primary gastric cancer: towards the prediction of lymph node status
    Alberto Marchet
    Clinica Chirurgica II, Dipartimento di Scienze Oncologiche e Chirurgiche, Istituto Oncologico Veneto IRCCS and University of Padova, Padova, Italy
    Ann Surg Oncol 14:1058-64. 2007
  3. ncbi Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer
    Claudio Belluco
    Department of Surgery, CRO IRCCS, National Cancer Institute, Via Franco Gallini, 2, 33081 Aviano PN, Italy
    Ann Surg Oncol 14:2470-6. 2007
  4. ncbi Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks
    Heiko Fensterer
    Department of Internal Medicine I, University of Ulm, Ulm, Germany
    BMC Cancer 7:58. 2007
  5. ncbi Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies
    Claudio Belluco
    Department of Surgical Oncology, CRO IRCCS, National Cancer Institute, Aviano, Italy
    Ann Surg Oncol 18:3686-93. 2011
  6. ncbi Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy
    Julia D Wulfkuhle
    Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110, USA
    J Proteome Res 7:1508-17. 2008
  7. ncbi Nanotechnology in clinical proteomics
    David H Geho
    Nanomed 2:1-5. 2007
  8. ncbi The blood peptidome: a higher dimension of information content for cancer biomarker discovery
    Emanuel F Petricoin
    Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas Virginia 20110, USA
    Nat Rev Cancer 6:961-7. 2006
  9. ncbi Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy
    Emanuel F Petricoin
    US Food and Drug Administration National Cancer Institute Clinical Proteomics Program, Office of Cellular and Gene Therapy, Center for Biologics Evaluation and Research, FDA, Bethesda, MD, USA
    J Clin Oncol 23:3614-21. 2005
  10. ncbi Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma
    Antonello D'Arrigo
    Research and Innovation Company, Padova, Italy
    Int J Cancer 115:256-62. 2005

Collaborators

Detail Information

Publications12

  1. ncbi Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discovery
    Riccardo Alessandro
    Department of Biopathology and Biomedical Methodology, Universita di Palermo, Palermo, Italy
    Clin Colorectal Cancer 4:396-402. 2005
    ..Together, these 2 technologies have been shown to advance the field and may be important new steps in diagnosis, prognosis, and treatment of colorectal cancer...
  2. ncbi Gene expression profile of primary gastric cancer: towards the prediction of lymph node status
    Alberto Marchet
    Clinica Chirurgica II, Dipartimento di Scienze Oncologiche e Chirurgiche, Istituto Oncologico Veneto IRCCS and University of Padova, Padova, Italy
    Ann Surg Oncol 14:1058-64. 2007
    ..The aim of this study was to screen the genome in the search of primary gastric cancer gene expression profiles that might predict lymph node status...
  3. ncbi Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer
    Claudio Belluco
    Department of Surgery, CRO IRCCS, National Cancer Institute, Via Franco Gallini, 2, 33081 Aviano PN, Italy
    Ann Surg Oncol 14:2470-6. 2007
    ..Mass spectrometry (MS)-based profiling was used to determine whether ion fingerprints could distinguish women with stage 1 breast cancer from women without breast cancer...
  4. ncbi Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks
    Heiko Fensterer
    Department of Internal Medicine I, University of Ulm, Ulm, Germany
    BMC Cancer 7:58. 2007
    ..Multicentric clinical studies represent an ideal source of well documented archived material for this type of analyses...
  5. ncbi Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies
    Claudio Belluco
    Department of Surgical Oncology, CRO IRCCS, National Cancer Institute, Aviano, Italy
    Ann Surg Oncol 18:3686-93. 2011
    ..We analyzed long-term outcome of cT3 rectal cancer treated by neoadjuvant CRT in relation to ypCR and type of surgery...
  6. ncbi Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy
    Julia D Wulfkuhle
    Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110, USA
    J Proteome Res 7:1508-17. 2008
    ..Analysis of biopsy material from clinical trials for targeted therapeutics demonstrates the feasibility and utility of comprehensive signal pathway activation profiling for molecular analysis...
  7. ncbi Nanotechnology in clinical proteomics
    David H Geho
    Nanomed 2:1-5. 2007
  8. ncbi The blood peptidome: a higher dimension of information content for cancer biomarker discovery
    Emanuel F Petricoin
    Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas Virginia 20110, USA
    Nat Rev Cancer 6:961-7. 2006
    ..Measuring panels of peptidome markers might be more sensitive and specific than conventional biomarker approaches. We discuss the advantages and disadvantages of various methods for studying the peptidome...
  9. ncbi Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy
    Emanuel F Petricoin
    US Food and Drug Administration National Cancer Institute Clinical Proteomics Program, Office of Cellular and Gene Therapy, Center for Biologics Evaluation and Research, FDA, Bethesda, MD, USA
    J Clin Oncol 23:3614-21. 2005
    ..We provide a vision for individualized combinatorial therapy based on proteomic mapping of phosphorylation end points in clinical tissue material...
  10. ncbi Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma
    Antonello D'Arrigo
    Research and Innovation Company, Padova, Italy
    Int J Cancer 115:256-62. 2005
    ....
  11. ncbi Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: analysis of a large European monoinstitutional experience
    Donato Nitti
    Department of Oncological and Surgical Science, University of Padova, Italy
    Ann Surg Oncol 10:1077-85. 2003
    ....
  12. ncbi Lymphadenectomy in patients with gastric cancer. A critical review
    Donato Nitti
    Department of Oncological and Surgical Sciences, Clinica Chirurgica II, University of Padua, Italy
    Suppl Tumori 2:S35-8. 2003
    ..The aim of the present study was therefore to evaluate the outcome following extended lymphadenectomy, and the prognostic significance of lymph node status, in a group of patients who underwent radical resection for gastric cancer...